# ACEA Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acea-biosciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.aceabio.com
- Latest round: Series E (Apr 1, 2016)
- Investors on record: 1

## About

ACEA Biosciences, Inc. specializes in advanced flow cytometry and real-time live cell analysis solutions, providing innovative technologies to enhance research in immunotherapy, infectious diseases, and drug discovery.Founded in 2002 and headquartered in San Diego, US, ACEA Biosciences, Inc. focuses on developing flow cytometry and live cell analysis solutions. In September 2018, the company was acquired by Agilent Technologies Inc. for USD 250 million. The acquisition was finalized in November 2018.ACEA Biosciences, now part of Agilent, specializes in advanced flow cytometry and real-time live cell analysis solutions tailored for research applications in areas such as immunotherapy, infectious diseases, and drug discovery. The core product offerings include Agilent's NovoCyte flow cytometers and xCELLigence Real-Time Cell Analysis (RTCA) instruments. The NovoCyte flow cytometers provide researchers with high-quality data in an intuitive platform, facilitating the acquisition and analysis of experimental data. The xCELLigence RTCA instruments utilize biosensors to monitor cell behavior in a label-free manner, enabling users to track immune cell activity and virus-induced cytopathic effects in real time. Key customer segments include academic institutions, pharmaceutical companies, and biotechnology firms, with a geographical focus that spans North America, Europe, and Asia.ACEA Biosciences generates revenue primarily through the sale of its flagship products, including the NovoCyte series and xCELLigence RTCA instruments, which are sold directly to clients in the research and healthcare sectors. The company operates on a B2B model, engaging directly with universities, research institutions, and pharmaceutical companies. Transactions typically involve the purchase of lab instruments along with optional reagents and software, creating a comprehensive solution for clients' experimental needs. This approach fosters long-term partnerships, enabling continuous updates and technological enhancements for clients as their research requirements evolve.The recent acquisition by Agilent Technologies provides ACEA Biosciences the opportunity to leverage additional resources for future growth. Although specific new product launches have not been detailed, the integration into Agilent is expected to enhance their product portfolio in cell analysis technologies. ACEA is well-positioned to expand into new markets, particularly in Asia, where there is increasing demand for sophisticated research tools. The USD 250 million from the acquisition will support these initiatives, allowing for investment in R&D and market expansion.

## Funding rounds

- Series E, Apr 1, 2016 — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series E